|
|
|
|
Vol. 62, Issue 6, 1464-1470, December 2002
Department of Pharmaceutical Sciences, College of Pharmacy and
Allied Health Professions, St. John's University, Queens, New York
Chronic opioid agonist treatment produces tolerance and in some cases
opioid receptor internalization and down-regulation. Both morphine and
etorphine induce tolerance; however, only etorphine produces µ-opioid
receptor (µOR) down-regulation. In vitro studies implicate dynamin-2
(DYN-2) and G-protein receptor kinase-2 (GRK-2) in these processes.
Therefore, we examined etorphine and morphine effects on regulation of
GRK-2 and DYN-2 in mouse spinal cord. Mice were treated for 7 days with
etorphine (200 µg/kg/day infusion) or morphine (40 mg/kg/day infusion + one 25-mg implant pellet). Controls were implanted with a placebo
pellet. On the 7th day after implantation mice were tested for i.t.
[D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
(DAMGO) analgesia. In other mice, spinal cord was removed for
[3H]DAMGO binding studies or GRK-2 and DYN-2 protein and
mRNA abundance were determined. Both etorphine and morphine produced
significant tolerance (ED50 shift = 7.6- and 7.3-fold
for morphine and etorphine, respectively). Etorphine decreased spinal
µOR density by
30%, whereas morphine did not change µOR
density. Etorphine increased (
70%) DYN-2 protein abundance and
decreased its mRNA (31%), whereas it had no effect on GRK-2 protein
and mRNA abundance. Morphine had no effect on either DYN-2 or GRK-2
protein or mRNA abundance. These data raise the possibility that
unequal receptor regulation by etorphine and morphine might be due to
differential regulation of trafficking proteins. Overall, receptor
down-regulation associated with chronic etorphine treatment may
accelerate dynamin-related activity. Finally, the decrease in DYN-2
mRNA may be related to stabilization of DYN-2 protein abundance, which
might inhibit transcription.
This article has been cited by other articles:
![]() |
M. S. Virk and J. T. Williams Agonist-Specific Regulation of {micro}-Opioid Receptor Desensitization and Recovery from Desensitization Mol. Pharmacol., April 1, 2008; 73(4): 1301 - 1308. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sirohi, P. Kumar, and B. C. Yoburn {micro}-Opioid Receptor Up-Regulation and Functional Supersensitivity Are Independent of Antagonist Efficacy J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 701 - 707. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Wenk, J.-D. Brederson, and C. N. Honda Morphine Directly Inhibits Nociceptors in Inflamed Skin J Neurophysiol, April 1, 2006; 95(4): 2083 - 2097. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Clark and J. R. Traynor Endogenous Regulator of G Protein Signaling Proteins Reduce {micro}-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 809 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Dang and J. T. Williams Chronic Morphine Treatment Reduces Recovery from Opioid Desensitization J. Neurosci., September 1, 2004; 24(35): 7699 - 7706. [Abstract] [Full Text] [PDF] |
||||